Kornimate/medical-research-clean huggingface dataset:
the complex regional pain syndrome (crps) is a chronic pain condition. this is a preliminary study to explore and test clinical hypothesis. they suppose that crps patients have impairment in their mental or motor imagery abilities.

Conditions: Complex Regional Pain Syndromes; Musculoskeletal Pain Disorder; Healthy

Summary: medical functional imagery seems to demonstrate that patients suffering from complex regional pain syndrome (crps) have cortical modifications that alter their motor (or mental) imagery capacities. nowadays, the use of motor imagery exercises are used in conventional rehabilitation treatments. but, in clinical practice, no study has verified if patients with crps desmonstrate problems in their motor imagery capacities. the miq-rs (motor imagery questionnaire - revised second) is a valid, reliable and translated into french questionnaire to measure patients' capacities to do mental imagery. in this study, we compare 3 groups of 50 patients : healthy patients, patients with crps and patients with musculoskeletal disorder without crps. every patient will take the miq-rs for the right and left body side. we hypothesis that patients with crps have more deficit than the 2 others to realise motor imagery.


Eligibility criteria:
inclusion criteria: * patient with french healthcare affiliation * adult patient (\> 18 years old) * patient with bachelor degree minimum * patient practicing less than 150 minutes of moderate to intense physical activity per week specific inclusion criteria for crps group : * patient followed in the evaluation and treatment pain center (university hospital of nimes) * patient with secondary crps due to a traumatism or a surgery specific inclusion criteria for musculoskeletal group : * patient with musculoskelettal disorder on a limb (upper or lower) * patient followed in the university hospital of nimes non inclusion criteria : * patient who participates in another category 1 research * patient in a exclusion period in another study * patient under legal protection, under guardianship or under curatorship * patient for whom it is impossible to give clear information. * pregnant, parturient or breastfeeding patient. * patient with amputation on one of his limb * patient with visual cecity * patient who has already practiced mental imagery * patient with neurological impairment * patient with chronic low back pain and fibromyalgia specific non inclusion criteria for musculoskeletal group and healthy group : -patient with crps specific non inclusion criteria for crps group : * secondary crps to cva (cerebrovascular accident) * patient receiving lymph node block treatment between the inclusion visit and the follow-up visit specific non inclusion criteria for musculoskeletal disorder group : * patient with secondary musculoskeletal disorder to a cva exclusion criteria : * questionnaire miq-rs not completed or non respect with the research protocol * pathology discovered incompatible with the study criteria

Keywords: complex regional pain syndromes motor imagery mental imagery miq-rs pilot study comparison groups crps
a multicenter study of iomeron®-400 used with multi-detector computed tomography angiography (mdcta)

Conditions: Aortic Disorders; Carotid Disease; Pulmonary Disease; Peripheral Artery Disease

Summary: this is a phase iv multicenter, open-label study and is being implemented in order to assess diagnostic image quality of mdcta in subjects undergoing computed tomography angiography (cta) of the thoraco-abdominal aorta, and the carotid, pulmonary and peripheral arteries with iomeron.

this is a phase iv multicenter, open-label study and is being implemented in order to assess diagnostic image quality of mdcta in subjects undergoing computed tomography angiography (cta) of the thoraco-abdominal aorta, and the carotid, pulmonary and peripheral arteries with iomeron. the hypothesis is that iomeron used at a high concentration will provide good diagnostic image quality. the investigators will also function as readers and evaluate the images on-site. efficacy analysis will be based on the on-site evaluations. imaging conditions will be representative of those used in routine clinical practice. the study will be conducted at approximately 10-20 sites in china. each site may enroll approximately 40 subjects in this study. approximately 400 subjects will be enrolled in order to obtain 360 evaluable subjects who undergo elective mdcta of the thoraco-abdominal aorta, or carotid, pulmonary or peripheral arteries.

Eligibility criteria:
inclusion criteria: 1. provides written informed consent and is willing to comply with protocol requirements 2. is at least 18 years of age. 3. is scheduled to undergo an elective thoraco-abdominal aorta, carotid, pulmonary or peripheral mdcta examination. exclusion criteria: 1. is a pregnant or lactating female. exclude the possibility of pregnancy: by testing on site at the institution (serum or urine βhcg) within 24 hours prior to the start of investigational product administration, by surgical history (e.g., tubal ligation or hysterectomy),post-menopausal with a minimum 1 year without menses; 2. has any known allergy to one or more of the ingredients of iomeron or a history of hypersensitivity to iodinated contrast agents; 3. has moderate to severe renal impairment; 4. has received an investigational compound and/or medical device within 30 days before admission into this study; 5. has been enrolled previously to this study 6. has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations.
evaluating the role of the addition of ovarian function suppression (ofs) to tamoxifen in young women

Conditions: Breast Cancer

Summary: the purpose of this study is to compare 5-year disease free survival rate (dfs rate) between the hormone receptor positive breast cancer patients who were added goserelin to tamoxifen for ovarian function suppression after neo-/adjuvant cytotoxic chemotherapy and the hormone receptor positive breast cancer patients who were treated with tamoxifen.

* to compare overall survival(os) between the patients added goserelin(zoladextm) to tamoxifen and the patients treated with tamoxifen alone in premenopausal status * to compare 5-year disease free survival rate (dfs rate) between the patients who took tamoxifen only in postmenopause and the patients added goserelin(zoladextm) to tamoxifen for inducing ovarian function suppression in premenopause * to determine the tolerability and safety of tamoxifen with or without concomitant zoladex

Eligibility criteria:
inclusion criteria: 1. patients must have undergone excision of the primary breast mass, proven histologically to be invasive breast adenocarcinoma. 2. patients must be within 3 months after the last cycle of chemotherapy. 3. patients must have the history of normal menstruation prior to the start of chemotherapy. 4. stage i, ii or iii 5. woman, less than or equal to 45 years of age 6. hormone receptor status : er+ve and/or pgr+ve 7. who performance status 0, 1 or 2. 8. patients who were treated with cytotoxic chemotherapy in pre- or post- surgery. 9. adequate haematological function defined by haemoglobin 10g/dl, neutrophil count 1.5x109/l and platelets 100x109/l. 10. adequate hepatic function defined by ast and alt 2.5xupper limit of normal. alkaline phosphatase 5xupper limit of normal, unless bone metastases in the absence of liver disease. renal function adequate defined by creatinine\<175mmol/l. exclusion criteria: 1. patients whose primary breast cancer was classified as: * er(-),er unknown 2. patients with the history of hysterectomy or oophorectomy 3. sarcomas or squamous cell carcinomas of the breast are not eligible. 4. patients with malignancies (other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell / squamous cell carcinoma of the skin. 5. investigational drugs given within the previous 4 weeks. 6. patients known to be on any unlicensed non-cancer investigational agent. 7. patients with thrombocytopaenia (platelets \<100 x 109/l or on anti- coagulant therapy (contra-indicated due to risk of bleeding with i.m. injection of zoladex). 8. patients treated with cmf(cyclophosphamide/methotrexate/5-fluorouracil) as prior chemotherapy 9. patients who are pregnant or lactating are ineligible.

Keywords: premenopause ovarian function suppression tamoxifen
ventilation distribution after bariatric surgery

Conditions: Bariatric Surgery Candidate; Atelectasis, Postoperative Pulmonary

Summary: obese patients have an increased risk of developing post-operative respiratory complications due to their comorbidities. they have a restrictive ventilatory defect with reduction of lung volumes and expiratory flow limitation, higher airway resistance and collapsibility of the upper respiratory tract. these abnormalities are worsened by general anesthesia and opioid administration. it has been proved that oxygen therapy with hfnc (high flow nasal cannula) increases lung volumes through a continuous positive airway pressure (cpap)-effect. this also improves gas exchange and decreases anatomical dead space. at the present time, cpap represents the gold standard for the prevention of postoperative pulmonary complications. the purpose of this study is to evaluate lung ventilation, gas exchange and comfort with hfnc compared with cpap during the post-operative period in patients who undergo laparoscopic bariatric surgery.

immediately after bariatric surgery, patients will follow a pre-determined schedule of oxygen therapy with conventional facemask (from the beginning to minute 10), hfnc (with a flow of 40 l/min from minute 11 to 20, 60 l/min from minute 21to 30, 80 l/min from minute 31 to 40, 100 l/min from minute 41 to 50, 80 l/min from minute 51 to 60, 60 l/min from minute 61 to 70, 40 l/min from minute 71 to 80), conventional facemask again (washout, from minute 81 to 90) and cpap (10 cmh2o, from minute 91 to 100). lung ventilation will be evaluated with electrical impedance tomography (eit), which measures thoracic impedance variations related to changes in lung aeration. at the end of each 10 minutes-period the following data will be collected: electrical impedance tomography data (to calculate the global inhomogeneity index, δ end-expiratory lung impedance and tidal impedance variation), hemodynamic parameters, respiratory rate, spo2, pain (numerical rating scale), level of sedation (ramsey score) and patient comfort (modified borg scale). an arterial blood gas will be collected at the end of the following steps: baseline facemask, hfnc 40 and 100 l/min, washout facemask and cpap. data about anesthetic/analgesic drugs and ventilation parameters will also be collected.

Eligibility criteria:
inclusion criteria: * patient's consent to the trial * candidate to laparoscopic bariatric surgery (sleeve gastrectomy or roux-en-y gastric bypass) * bmi 35-50 kg/m2 * asa class 1-3 exclusion criteria: * obesity hypoventilation syndrome * contraindication to eit (e.g. implantable cardioverter-defibrillator)

Keywords: high flow nasal cannula bariatric surgery postoperative atelectasis electrical impedance tomography
mri-guided holmium-166 radioembolization

Conditions: Primary Liver Cancer; Non-Resectable Hepatocellular Carcinoma

Summary: to investigate the safety and feasibility of a personalized ho-166-plla-ms tare approach by using mri guidance in inoperable patients with hcc.


Eligibility criteria:
inclusion criteria: 1. diagnosis of hepatocellular carcinoma bclc stage b or c 2. at least one lesion of 10 mm or more in the longest diameter on contrast-enhanced mri/ct 3. patient is eligible for tare as determined by the tumour board (in dutch: mdo) 4. patient has a life expectancy of 12 weeks or longer 5. patient has a who performance score of 0-2 exclusion criteria: 1. extrahepatic disease that cannot be targeted during the tare session (enlarged lymph nodes in the liver hilus are allowed) 2. radiation therapy, chemotherapy or major surgery within 4 weeks before treatment 3. serum bilirubin \> 2.0 x the upper limit of normal 4. alat, asat, alkaline phosphatase (af) \> 5x the upper limit of normal 5. leukocytes \<4.0 \* 109/l or platelet count \<60 \* 109/l 6. significant heart disease that in the opinion of the physician increases the risk of ventricular arrhythmia. 7. pregnancy or breast feeding 8. disease with increased chance of liver toxicity, such as primary biliary cirrhosis or xeroderma pigmentosum 9. patients ineligible to undergo mr-imaging (claustrophobia, metal implants, etc) 10. portal vein thrombosis of the main branch (more distal branches are allowed) 11. untreated, active hepatitis 12. body weight \> 150 kg (because of maximum table load) 13. severe allergy for i.v. contrast (iomeron, dotarem and/or primovist) 14. lung shunt \> 30 gy, as calculated using scout dose 166ho spect/ct. 15. uncorrectable extrahepatic deposition of scout dose activity. activity in the falciform ligament, portal lymph nodes or gallbladder are accepted. 16. unstable final catheter position due to hepatic artery anatomy, which might lead to dislocation of the catheter during transfer to the mri.

Keywords: hepatocellular carcinoma radioembolization tare
staphylococcal toxins in atopic dermatitis and eczema herpeticum

Conditions: Atopic Dermatitis; Staphylococcus Aureus; Bacterial Toxins; Immune Response; Cytokines; T Cells Subsets

Summary: atopic dermatitis (ad) is the most common chronic inflammatory skin disease. clinical studies have demonstrated a link between staphylococcal skin colonization and the pathogenesis of ad, but the implication of bacterial virulence factors remains largely uncharacterized. finally, ad is often associated with herpes simplex skin infections. the aim of this project is to investigate the role of staphylococcal toxins in the exacerbation and maintenance of atopic skin inflammation and in the occurrence of infectious complications such as eczema herpeticum.


Eligibility criteria:
inclusion criteria: * patients with moderate ad (scorad between 25 and 50) or severe ad (scorad\> 50) * skin lesions in the forearms * free subject, without neither guardianship, wardship nor subordination * patient with social security * informed and signed consent by the patient after clear and loyal information on the study exclusion criteria: * age \< 18 year-old * patients with mild ad (scorad \< 25) * patients without skin lesions in the forearms * patients treated with dermocorticoid or calcineurin inhibitor for less than two weeks * patients under systemic treatment : methotrexate, ciclosporin, mycophenolate mofetil, azathioprine, general corticosteroids for less than 4 weeks * patients under biological treatment : dupilumab for less than 5 half-lives * patient without social security * pregnant and nursing women
health literacy intervention for african americans with diabetes

Conditions: Uncontrolled Diabetes

Summary: disparities in diagnosis and control of type 2 diabetes mellitus are most evident in african americans (aas) with lower socioeconomic status. health literacy is an important predictor of adequate self-management and control of diabetes. the purpose of this pilot study was to test the feasibility and preliminary efficacy of a health literacy-enhanced diabetes intervention -prevention through lifestyle intervention and numeracy (plan) 4 success-diabetes, in inner-city, low-income aas with uncontrolled diabetes. to evaluate the feasibility, acceptability, and preliminary efficacy of the intervention, the investigators conducted a pilot study with 24-week follow-up. the investigators that participation in the plan 4 success-diabetes intervention would be associated with a reduction in glucose outcomes and improvements in psychosocial variables.


Eligibility criteria:
inclusion criteria: * african americans residing in baltimore, maryland * had uncontrolled diabetes (defined as hba1c\>7%) exclusion criteria: * unable to give informed consent * physical or mental health conditions that could limit active participation in the study (e.g., blindness in both eyes, severe immobility, psychiatric diseases) * hematological condition that would affect hba1c assay, e.g., hemolytic anemia, sickle cell anemia

Keywords: type 2 diabetes african american numeracy self-management glucose control
techniques used in evaluation of gingival phenotype

Conditions: Gingival Recession

Summary: this study evaluates the 4 different techniques used in clinical measurement of gingival phenotype. 1) tranclusency of unc-15 periodontal probe, 2) transgingival probing with endodontic file (#20), 3)transgingival probing with modified florida probe and 4) translucency colorvue biotype probe. the aim of our study is to evaluate the reliability and applicability of the current examination methods recommended in order to improve the deficiencies of the traditional examination methods used in the evaluation of the gingival phenotype.


Eligibility criteria:
inclusion criteria: * systemically healthy individuals, * periodontal healthy individuals with a whole mouth plaque score of 15% and a whole mouth bleeding score of less than 15%, * individuals who have not undergone periodontal treatment (subgingival curettage, gingivectomy, crown lengthening, etc.) in the last 6 months, * absence of dental compensations of skeletal malocclusion. exclusion criteria: * individuals who smoke and have a history of smoking, * individuals who have undergone orthodontic treatment, * individuals using drugs that may cause gingival hyperplasia (immunosuppressive drugs, calcium channel blockers, anticonvulsant drugs, etc.) * individuals who are in pregnancy or lactation period, * presence of structural defects, crowns or large restorations in the maxillary anterior teeth to be measured, * the presence of missing or supernumerary teeth in the maxillary anterior teeth to be measured,

Keywords: gingival phenotype gingival thickness
a combination therapy study of mk-2206 and azd6244 in participants with advanced solid tumors (mk-2206-010)

Conditions: Locally Advanced or Metastatic Solid Tumors

Summary: this study will investigate the safety and tolerability of combination therapy with mk-2206 and azd6244 (selumetinib) and determine the maximum tolerated dose (mtd) and recommended phase 2 dose (rptd) for this drug combination in the treatment of participants with locally advanced or metastatic solid tumors. preliminary efficacy data will also be collected. the primary hypotheses for this study are that: 1) the dose-limiting toxicities (dlts) observed in participants with locally advanced or metastatic solid tumors after administration of combination therapy with mk-2206 and azd6244 will be dose-dependent and allow for identification of the mtd, and 2) oral administration of combination therapy with mk-2206 and azd6244 to participants with advanced solid tumors will be generally well-tolerated.


Eligibility criteria:
inclusion criteria: * participant has confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or therapies known to provide clinical benefit, or for whom efficacious standard therapy or any other therapy known to provide clinical benefit does not exist * participant has no history of prior cancer, except certain cervical, skin, or prostate cancers, or has undergone potentially curative therapy with no evidence of disease for 5 years * at least 18 years of age * participant is able to swallow oral medications * for participants enrolled in the mtd expansion cohorts, must have a diagnosis of kirsten rat sarcoma viral oncogene homolog (kras) tumor-type non small-cell lung cancer (nsclc). additional tumor types (with specific mutations) may be added to the mtd expansion cohorts after discussion between sponsor and investigator exclusion criteria: * participant has had chemotherapy, radiotherapy or biological therapy within 4 weeks of entering the study * participant is currently participating in or has participated in a study of an investigational compound or device within 30 days or 5x the compound's half-life of cycle 1, day 1 * participant has known central nervous system metastases and/or carcinomatous meningitis * participant has a primary central nervous system tumor or spinal cord compression * participant is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse * participant is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study * participant is human immunodeficiency virus (hiv) positive * participant is has history of hepatitis b or c or active hepatitis a * participant has a history or current evidence of heart disease * participant has uncontrolled high blood pressure * participant has poorly controlled diabetes
ppk study based on quantitative pharmacology in patients with pamipril

Conditions: Ovarian Cancer

Summary: this is a non-intervention, prospective, one-arm, observational real-world clinical trial. the researchers plan to recruit at least 50 qualified patients. the main purpose of this study was to establish a population pharmacokinetic model of pamiparib and to explore the correlation between its pharmacokinetic parameters and adverse reactions.

in recent years, the advent of poly(adp-ribose) polymerase(parp) inhibitors is one of the important breakthroughs in the field of tumor-targeted therapy, and its therapeutic effect on ovarian cancer is quite significant pamiparib is a potent, selective, oral parp 1/2 inhibitor. in preclinical models, pamiparib demonstrated parp-dna complex trapping, brain penetration, antitumor activity, and inhibition of parylation. therefore, at least 50 patients using pamiparib will be included. before and after treatment, the laboratory examination data ，blood concentration ，combined medication and adverse events of the patients will be collected. the population pharmacokinetic model of pamiparib was established to evaluate the correlation between pharmacokinetic parameters and adverse reactions.

Eligibility criteria:
inclusion criteria: 1. the age of the patient is ≥ 18 years old and less than 80 years old. 2. receive treatment with pamipalil. 3. the patient signed a written informed consent form. exclusion criteria: 1. the expected survival time may be less than the treatment cycle. 2. is being treated with other systemic trial drugs. 3. there are other factors that the researchers think are not suitable for joining the group.

Keywords: ovarian cancer pamiparib